Results 201 to 210 of about 182,114 (270)
Dasatinib and quercetin prevent alveolar bone loss in aged mice
Abstract Background Recent findings have associated alveolar bone loss (ABL) with the presence of senescent cells. Aging and the accumulation of senescent cells are associated with a pro‐inflammatory environment which may exacerbate tissue damage.
Luisa S. Battistelli +7 more
wiley +1 more source
Programmed Cell Death in Chronic Rhinosinusitis. [PDF]
Liu X +5 more
europepmc +1 more source
Abstract Objectives Exclusive enteral nutrition (EEN) is the first‐line treatment for pediatric Crohn's disease, but its mechanisms of action remain poorly understood. Our aim was to identify the mechanisms that could explain the anti‐inflammatory effects of EEN, studying the nutritional composition and transforming growth factor‐β (TGF‐β) effects, in ...
Kawthar Boumessid +6 more
wiley +1 more source
Co-Exposure to Aflatoxin B1 and Patulin Induces Hepatic Injury in Mice and HepG2 Cells by Activating Oxidative Stress and Apoptosis. [PDF]
Liu Y +6 more
europepmc +1 more source
Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives
Abstract Cancer is constantly rising mortality rates due to its late prognosis, poor management, and expensive treatment. Multi‐sectoral approaches for cancer management include hygienic practices, synthetic drug exploitation, radiation therapy, and diet modifications.
Muhammad Maaz +10 more
wiley +1 more source
Apoptosis signaling and cancer targeted therapy: from bench to bespoke. [PDF]
Huang X +5 more
europepmc +1 more source
Abstract INTRODUCTION Bromelain, a complex mixture of proteolytic enzymes primarily extracted from plants of the Bromeliaceae family, has gained prominence because of its broad industrial applicability, particularly in the food, pharmaceutical and cosmetic sectors.
Genésio José da Silva Neto +6 more
wiley +1 more source
Disrupting the Undruggable: Emerging Modalities for Targeting Protein-Protein Interactions in Oncology. [PDF]
El-Tanani M +4 more
europepmc +1 more source
Cutaneous Rosai‐Dorfman Disease With MAP2K1 Mutation Treated With Encorafenib and Binimetinib
ABSTRACT Rosai‐Dorfman disease (RDD) is a rare histiocytic disorder with unifocal to multisystemic involvement. Activating mutations in the MAPK/ERK pathway can occur in up to 50% of RDD cases. We report a case of cutaneous RDD (C‐RDD) with facial and truncal lesions harboring an activating MAP2K1 (MEK1) mutation that showed a complete response to a ...
Melike Ak +2 more
wiley +1 more source

